List of Omontys drug patents
Omontys is owned by Takeda Pharms Usa.
Omontys contains Peginesatide Acetate.
Omontys has a total of 6 drug patents out of which 0 drug patents have expired.
Omontys was authorised for market use on 27 March, 2012.
Omontys is available in solution;intravenous, subcutaneous dosage forms.
Omontys can be used as treatment of anemia due to chronic kidney disease.
The generics of Omontys are possible to be released after 02 June, 2026.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7084245 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(1 year, 1 month from now) | |
| US7414105 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(1 year, 1 month from now) | |
| US7919118 | TAKEDA PHARMS USA | Spacer moiety for poly (ethylene glycol) modified peptide based compounds |
May, 2024
(1 year, 1 month from now) | |
| US7528104 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(1 year, 1 month from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7550433 | TAKEDA PHARMS USA | Erythropoietin receptor peptide formulations and uses |
Jun, 2026
(3 years from now) | |
| US7919461 | TAKEDA PHARMS USA | Erythropoietin receptor peptide formulations and uses |
Jun, 2026
(3 years from now) | |
Drugs and Companies using PEGINESATIDE ACETATE ingredient
Market Authorisation Date: 27 March, 2012
Treatment: Treatment of anemia due to chronic kidney disease
Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS
OMONTYS family patents
32
United States
9
Japan
6
Korea, Republic of
6
European Union
5
New Zealand
4
South Africa
4
Mexico
4
Australia
4
Norway
4
Brazil
4
China
4
EA
4
Canada
3
Iceland
2
Denmark
2
Hong Kong
2
Slovenia
2
Costa Rica
2
Singapore
2
Croatia
2
Portugal
2
Cyprus
2
Spain
2
Poland
2
Ukraine
1
Israel
1
OA
1
Austria
1
Morocco
1
AP
1
Germany
1
Yugoslavia
1
Georgia
1
ME
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic